Targeted protein degradation offers an alternative modality to classical inhibition and holds the promise of addressing previously undruggable targets to provide novel therapeutic options for patients. Nature Communications volume 13, Article number: 5969 ( 2022)
A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo
0 kommentar(er)
